Clinical trials: Primary Hypercholesterolemia
Hypercholesterolemia
Long-Term Safety and Tolerability of Ezetimibe (SCH 58235, MK-0653) With Atovastatin (P02154, MK-0653-017)
The purpose of this study is to examine the long-term safety and tolerability of ezetimibe (SCH 58235) 10 mg once daily or placebo in combination with atorvastatin (10 to 80 mg/day) for up to 12 consecutive months in participants…
- Trial name
- NCT03882892
- Testing
- Ezetimibe, Atovastatin
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Mixed Hyperlipemia
MK0859 Dose-Ranging Study (0859-003)
To assess the cholesterol changing effects of MK0859 in patients with primary hypercholesterolemia or mixed dyslipidemia.
- Trial name
- NCT00325455
- Testing
- MK0859
- Volunteers
- 500 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Diabetes Mellitus, Type 2
Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)
This multicenter, randomized, double-blind, placebo-controlled study will assess, after 6 weeks of dosing, whether co-administration of ezetimibe 10 mg with simvastatin 20 mg will be more effective than treatment with doubling…
- Conditions
- Hypercholesterolemia, Diabetes Mellitus, Type 2, Coronary Disease
- Trial name
- NCT00423488
- Testing
- Ezetimibe 10 mg, Simvastatin 20 mg
- Volunteers
- 93 people
- Sponsor
- Organon and Co
Hypercholesterolemia
Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia
The present study is assessing the efficacy and safety of AVE5530 (25 mg and 50 mg) in add-on to ongoing treatment with high doses of statin in a double-blind manner in comparison with placebo, in the management of patients with…
- Trial name
- NCT00766688
- Testing
- AVE5530
- Where
- 13 sites in United States, Australia and 11 more
- Volunteers
- 643 people
- Sponsor
- Sanofi
Primary Hypercholesterolemia, Mixed Dyslipidemia
Study to Assess the Real World Effectiveness of Inclisiran in Chinese Adult Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
This is a multi-center, prospective, comparative and non-interventional cohort study involving two cohorts, one cohort (Inclisiran Cohort) of patients treated with inclisiran in certain special territories in China (eg.
- Trial name
- NCT05118230
- Testing
- Inclisiran
- Where
- 2 sites in China
- Volunteers
- 61 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Dyslipidemia
Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin.
- Trial name
- NCT00309777
- Testing
- Pitavastatin, Simvastatin
- Where
- 42 sites in Finland, Italy and 3 more
- Volunteers
- 857 people
- Sponsor
- Kowa Research Europe
Hypercholesterolemia, Hyperlipidemia
A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)
This is a study to assess the safety, efficacy, and tolerability of MK0859 in patients with primary hypercholesterolemia (large amounts of cholesterol in the blood) or mixed hyperlipidemia (high levels of LDL cholesterol…
- Trial name
- NCT00565292
- Testing
- MK0859
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia.
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with ezetimibe on cholesterol levels in subjects with primary dyslipidemia
- Trial name
- NCT00268697
- Testing
- Lapaquistat acetate, Lapaquistat acetate and ezetimibe, Ezetimibe
- Where
- 9 sites in Estonia, Latvia and 2 more
- Volunteers
- 1,267 people
- Sponsor
- Takeda
Hypercholesterolemia and Mixed Hyperlipidemia
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
The purpose of this study is to compare the effectiveness, safety of SYH2053 in Participants with primary hypercholesterolemia or mixed dyslipidemia. A total of 156 Participants were actually enrolled
- Trial name
- NCT07421232
- Testing
- Inclisiran (Leqvio®) 300mg
- Where
- China
- Volunteers
- 156 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy
The purpose of this study is to compare the effectiveness, safety of SYH2053 in participants with primary hypercholesterolemia (non-familial) or mixed dyslipidemia on a background of lipid-lowering therapy.
- Trial name
- NCT07421284
- Where
- China
- Volunteers
- 900 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Hypercholesterolemia, Dyslipidemias
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W [≤31 days]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic…
- Conditions
- Hypercholesterolemia, Dyslipidemias, Primary Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia
- Trial name
- NCT06568471
- Testing
- Lerodalcibep
- Where
- 18 sites in China
- Volunteers
- 210 people
- Sponsor
- Hasten Biopharmaceutical Co., Ltd.
Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
The purpose of this study is to evaluate the efficacy and safetyof co-administration of AD-2281 and AD-2282 in patients with Primary Hypercholesterolemia
- Trial name
- NCT06747936
- Testing
- AD-2281, AD-2282
- Where
- South Korea
- Volunteers
- 129 people
- Sponsor
- Addpharma Inc.
Hypercholesterolemia
Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia
The purpose of the study is to determine whether an Internet based compliance tool is superior to common diet counselling in patients with hypercholesterolemia.
- Trial name
- NCT00240357
- Testing
- Lifestyle Regulation
- Where
- 109 sites in Denmark
- Volunteers
- 1,175 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).
- Trial name
- NCT01812707
- Testing
- Alirocumab, Atorvastatin
- Where
- 4 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Sanofi
Hypercholesterolemia, Coronary Heart Disease
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Peripheral Vascular Disease, Cerebrovascular Accident
- Trial name
- HEROS (NCT00660764)
- Testing
- Rosuvastatin
- Sponsor
- AstraZeneca
Primary Hypercholesterolemia
Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers
The purpose of this study is to evaluate Pharmacokinetic Properties and Safety after administration of HCP1306 tablet and Co-administration of HGP0816 tablet, HGP1404 tablet in the healthy adults.
- Trial name
- NCT02941848
- Testing
- HGP0816, HGP1404, HCP1306
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypercholesterolemia
Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.
The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with simvastatin on cholesterol levels in subjects with primary dyslipidemia
- Trial name
- NCT00256178
- Testing
- Lapaquistat acetate and simvastatin, Simvastatin
- Where
- 53 sites in Czechia, Estonia and 5 more
- Volunteers
- 411 people
- Sponsor
- Takeda
Primary Hypercholesterolemiia, Mixed Dyslipidemia
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.
- Trial name
- TRICONOS (NCT06686615)
- Testing
- Bempedoic acid, Ezetimibe, Rosuvastatin
- Where
- 163 sites in Austria, Belgium and 3 more
- Volunteers
- 2,000 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Primary Hypercholesterolemia, Mixed Dyslipidemia
Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
This study is being done to learn more about evolocumab in Chinese people with primary hypercholesterolemia or mixed dyslipidemia.
- Trial name
- NCT03433755
- Testing
- evolocumab
- Where
- 31 sites in China
- Volunteers
- 259 people
- Sponsor
- Amgen